FATE
Fate Therapeutics Inc

6,412
Mkt Cap
$174.4M
Volume
937,072.00
52W High
$1.94
52W Low
$0.661
PE Ratio
-1.31
FATE Fundamentals
Price
$1.40
Prev Close
$1.50
Open
$1.38
50D MA
$1.18
Beta
1.66
Avg. Volume
1.76M
EPS (Annual)
-$1.15
P/B
0.84
Rev/Employee
$41,279.50
$9.08
Loading...
Loading...
News
all
press releases
Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations
Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +1.21% and -8.73%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Earnings Summary: Fate Therapeutics Q4
read more...
Benzinga·5d ago
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has been given a consensus recommendation of "Hold" by the nine research firms that are presently covering the stock, MarketBeat Ratings...
MarketBeat·5d ago
News Placeholder
Fate Therapeutics (FATE) to Release Earnings on Wednesday
Fate Therapeutics (NASDAQ:FATE) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average - What's Next?
Fate Therapeutics (NASDAQ:FATE) Stock Passes Above 50 Day Moving Average - Time to Sell...
MarketBeat·21d ago
News Placeholder
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have received a consensus recommendation of "Hold" from the nine analysts that are covering the firm, Marketbeat.com reports. One...
MarketBeat·1mo ago
News Placeholder
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets PR Newswire...
PR Newswire·1mo ago
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50 Day Moving Average - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) insider Cindy Tahl sold 10,589 shares of the business's stock in a transaction dated Friday, January 9th. The shares were sold at an average...
MarketBeat·2mo ago
<
1
2
...
>

Latest FATE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.